Strategies for the assessment of protein aggregates in pharmaceutical biotech product development

313Citations
Citations of this article
627Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Within the European Immunogenicity Platform (EIP) ( http://www.e-i-p.eu ), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods should be used during product development and make recommendations to the biotech community with regard to strategies for their application during the development of protein therapeutics. © 2010 The Author(s).

Cite

CITATION STYLE

APA

Den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., … Jiskoot, W. (2011, April). Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharmaceutical Research. https://doi.org/10.1007/s11095-010-0297-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free